Peptides & Building Blocks

Bis(2-Methyl-2-Propanyl) N,N'-Bis[(9H-Fluoren-9-Ylmethoxy)Carbonyl]-L-Cystinate

  • CAS No.139592-37-3
  • GradeIndustrial / Pharmaceutical
  • Availability● In Stock

Premium Fmoc-protected L-Cystine derivative for solid-phase peptide synthesis. High purity ≥98% with stable disulfide bond structure.

Request a Quote & Full COA

Product Technical Details

Product Overview

Bis(2-Methyl-2-Propanyl) N,N'-Bis[(9H-Fluoren-9-Ylmethoxy)Carbonyl]-L-Cystinate, commonly known as Fmoc-Cys(OtBu)2 dimer, represents a critical building block in modern peptide chemistry. This sophisticated amino acid derivative features dual Fmoc protection on the amine groups and tert-butyl ester protection on the carboxyl functionalities, linked via a stable disulfide bond. Designed specifically for researchers and industrial manufacturers, this compound ensures high fidelity during complex peptide assembly processes.

Our manufacturing process adheres to strict quality control protocols, guaranteeing minimal racemization and superior batch-to-batch consistency. The orthogonal protection strategy employed in this molecule allows for selective deprotection steps, making it an indispensable tool for synthesizing biologically active peptides containing cystine bridges.

Technical Specifications

ParameterValue
CAS Number139592-37-3
Molecular FormulaC44H48N2O8S2
Molecular Weight796.99 g/mol
Purity≥98% (HPLC)
AppearanceWhite Crystalline Powder
Storage Temperature0-5°C

Industrial Applications

This protected cystine derivative is primarily utilized in solid-phase peptide synthesis (SPPS) and solution-phase synthesis. It serves as a key precursor for developing therapeutic peptides, hormones, and enzyme inhibitors where disulfide bridges are essential for maintaining tertiary structure and biological activity. The Fmoc group offers stability under acidic conditions while being readily removable under basic conditions, providing flexibility in multi-step synthesis routes.

Pharmaceutical companies leverage this intermediate for drug discovery programs targeting metabolic disorders and oncology. The high purity specification ensures that downstream purification processes are streamlined, reducing overall production costs and time-to-market for final active pharmaceutical ingredients (APIs).

Quality Assurance and Handling

Every batch undergoes rigorous analytical testing including HPLC, NMR, and mass spectrometry to verify structural integrity and purity levels. We provide comprehensive Certificates of Analysis (COA) with each shipment. To maintain product stability, store the material in a tightly closed container within a cool, dry environment away from direct light and moisture. Proper handling procedures should be followed to prevent oxidation or hydrolysis during weighing and transfer operations.